In March 2026, the company underwent a significant corporate restructuring, changing its legal name to Verily Health, Inc. and transitioning from an LLC to a corporation following a $300 million investment round, with Alphabet becoming a significant minority investor and relinquishing its controlling stake. The company's primary technology infrastructure, the "Pre" platform, serves as an end-to-end ecosystem that harmonizes fragmented health data; clinical evidence generation solutions facilitate decentralized clinical trials; and care delivery includes virtual care solutions and personalized management programs for chronic conditions through its Onduo brand.
Cyborg Score Rationale
Verily demonstrates strong technology assets and platform capabilities with diversified products spanning diagnostics, wearables, and care delivery. The March 2026 restructuring and $300M investment round validate market demand, though execution risk remains as the company shifts toward commercialization away from pure R&D under independent ownership.
Top Insights
In March 2026, Verily underwent a corporate restructuring with a $300 million investment round that transformed the company from a majority Alphabet-controlled subsidiary to an independent corporation, signaling strong institutional validation for its platform and products.
Verily's products include the Verily Study Watch and continuous glucose monitoring devices developed in partnership with Dexcom, which serve healthcare providers and researchers to enhance clinical research and patient outcomes.
The company's clinical evidence generation solutions facilitate decentralized and hybrid clinical trials, utilizing tools like the Project Baseline platform to engage diverse populations and streamline data collection for research organizations.
Named Competitors
Wearable Cardiac Monitoring — Digital health and wearable monitoring platforms
Synthetic Biology & Biotech Platform — AI-driven synthetic biology and precision health solutions
Healthcare Innovation & Digital Health — Healthcare diagnostics, devices, and digital care solutions
Digital Health & Clinical Research — AI-powered health data and genomics platform
Recent Developments
(March 2026) Corporate restructuring: Legal name change to Verily Health, Inc.; $300M investment round; Alphabet transitions from controlling to minority investor
(October 2025) Launched consumer health app Verily Me at HLTH USA conference
(April 2025) Awarded $14.7M research grant from Michael J. Fox Foundation for Parkinson's disease molecular dataset generation
Open the full interactive Verily Life Sciences report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.